



# 9<sup>th</sup> eSEM SKELETAL ENDOCRINOLOGY MEETING

PROGRAMME

**19/20 FEBRUARY 2021**

PRESIDENT

**Andrea Giustina (I)**

SCIENTIFIC COMMITTEE

CO-CHAIRS

**J.P. Bilezikian (US), E. Canalis (US)**

MEMBERS

**M.L. Brandi (I), R. Civitelli (US)**

**A. Colao (I), S. Ferrari (CH), N. Napoli (I)**

**R. Nuti (I), R. Pacifici (US)**

**ORGANIZING SECRETARIAT and PROVIDER (ID 5468)**

A.I.C. Asti Incentives & Congressi

Ph. +39 050 598808 - Fax +39 050 0987825  
skeletal2021@aicgroup.it - www.aicgroup.it



## UNDER THE PATRONAGE OF

Città metropolitana di Milano

Ordine dei Medici Chirurghi e degli  
Odontoiatri della provincia di Milano

ASBMR - The American Society for Bone  
and Mineral Research

ES - Endocrine Society

ESE - European Society of Endocrinology

IDEA - International Vitamin D Expert Association

SIE - Società Italiana di Endocrinologia

SIOMMMS - Società Italiana dell'Osteoporosi  
del Metabolismo Minerale  
e delle Malattie dello Scheletro

Fondazione Giovanni Lorenzini

FONDAZIONE  
GIOVANNI LORENZINI  
MILAN, ITALY



GIOVANNI LORENZINI  
MEDICAL FOUNDATION  
NEW YORK, NY, USA

## Recorded Sessions (NO Italian CME)

FRIDAY  
19  
FEBRUARY  
2021

- 45 minutes **Rare Bone Disease lectures**  
**Chair: A. Linglart (F), G. Weber (I)**  
FOP: from bench to bedside - *R.J. Pignolo (US)*  
The identification of adult-presenting hypophosphatasia in a metabolic bone clinic setting - *R. Eastell (UK)*
- 50 minutes **Bone Neuroendocrine Symposium**  
**Chair: A.J. van der Lelij (NL), E. Ghigo (I)**  
Growth hormone, GHD and bone - *M. Fleseriu (US)*  
Medical treatment of acromegaly and osteopathy - *L. De Marinis (I)*  
Management of Cushing osteopathy - *A. Colao (I)*
- 50 minutes **Bisphosphonates: an update**  
**Chairs: J. Compston (UK), A. Scillitani (I)**  
Alendronate: Risks vs. Benefits of Long-term Treatment - *D.M. Black (US)*  
Bisphosphonates and cardiovascular risk - *R.A. Adler (US)*  
Zoledronate systemic effects beyond bone - *I.R. Reid (NZ)*

## Live Sessions (Italian time)

- 12.30 - 12.45 pm **Opening Ceremony**  
**Chair: A. Giustina (I)**
- 12.45 - 2.00 pm **Satellite Symposium: Hypovitaminosis D: a socio-economic problem with huge clinical impact which requires a structured intervention plan**  
**Chair: R Bernardini (I), A. Giustina (I)**  
The Epidemiologist perspective - *A. Odone (I)*  
The pharmacoeconomist perspective - *L. degli Esposti (I)*  
The clinician perspective - *S. Giannini (I)*  
The regulatory perspective - *R. Bernardini (I)*  
Discussion
- 2.00 - 3.00 pm **The changing spectrum of GIO**  
**Chairs: F. Casanueva (E), K. Saag (US)**  
Congenital adrenal hyperplasia - *H. Falhammar (S)*  
Prostate cancer - *S. Frara (I)*  
Gut microbiota - *L. McCabe (US)*  
Discussion
- 3.00 - 3.20 pm **Opening lecture**  
**Chairs: J. Bilezikian (US), E. Canalis (US)**  
Bone marrow adipose tissue: pathophysiological and clinical insights - *C. Rosen (US)*
- 3.20 - 4.20 pm **Session I: Assessment of fracture risk: do we need DXA?**  
**Chairs: C. Glüer (D), S. Gonnelli (I)**  
BSI - *F.M. Ulivieri (I)*  
Diffusion MRI - *A. Fathi Kazarooni (USA)*  
Microindentation - *N. Appelman-Dijkstra (NL)*  
Discussion
- 4.20 - 5.20 pm **Session II: Denosumab what's new**  
**Chairs: C. Marcocci (I), R. Rizzoli (CH)**  
Persistence of modeling based bone formation - *D. Dempster (US)*  
Diabetes related bone loss - *S. Ferrari (CH)*  
Safety - *P. Makras (GR)*  
Discussion
- 5.20 - 5.40 pm **Plenary Lecture**  
**Chairs: G. Bianchi (I), R. Civitelli (US)**  
Imminent fracture risk and the role of anabolic therapy - *F. Cosman (US)*

# Live Sessions (Italian time)

SATURDAY  
**20**  
FEBRUARY  
2021

- 2.00 - 2.15 pm **Mini Lecture**  
**Chairs:** B. Abrahamsen (DK), G. Banfi (I)  
The obese osteosarcopenic phenotype in breast cancer bone loss - A. Berruti (I)
- 2.15 - 3.30 pm **Session III: Bone metabolism and COVID-19**  
**Chairs:** P. Ebeling (Aus), M. Hewison (UK)  
Vitamin D - N. Binkley (US)  
Fractures - M. Doga (I)  
Hypocalcemia - A.M. Formenti (I)  
Antiosteoporotic treatment - A.M. Formenti (I)  
Discussion
- 3.30 - 4.45 pm **Session IV: Hypoparathyroidism a systemic disease**  
**Chairs:** M.L. Brandi (I), A. Giustina (I)  
Kidney - D. Shoback (US)  
Brain - L. Rejnmark (DK)  
Quality of life - H. Siggekkow (D)  
Perspectives on treatment - J.P. Bilezikian (US)  
Discussion
- 4.45 - 5.45 pm **Session V: Bone anabolic treatments**  
**Chairs:** I. Chiodini (I), R. Pacifici (US)  
Teriparatide - S. Minisola (I)  
Abaloparatide - J.P. Bilezikian (US)  
Novel approaches - E. Canalis (US)  
Discussion
- 5.45 - 6.30 pm **Session VI: Romosozumab**  
**Chairs:** S. Papapoulos (NL), M. Rauner (D)  
An update on clinical results - B. Langdahl (DK)  
An update on safety - N. Napoli (I)  
Discussion
- 6.30 - 6.50 pm **Closing lecture**  
**Chairs:** M. Barbagallo (I), R. Nuti (I)  
Osteodystrophy: what's new - G. Iolascon (I)
- 6.50 - 7.00 pm **Final discussion and conclusive remarks**  
**Chair:** A. Giustina (I)
- 7.00 - 7.10 pm **Italian CME test instructions**





## FACULTY

- B. ABRAHAMSEN (DK)  
R. ADLER (US)  
N. APPELMAN-DIJKSTRA (NL)  
G. BANFI (I)  
M. BARBAGALLO (I)  
R. BERNARDINI (I)  
A. BERRUTI (I)  
G. BIANCHI (I)  
J.P. BILEZIKIAN (US)  
N. BINKLEY (US)  
D.M. BLACK (US)  
M.L. BRANDI (I)  
E. CANALIS (US)  
F. CASANUEVA (E)  
I. CHIODINI (I)  
R. CIVITELLI (US)  
A. COLAO (I)  
J. COMPSTON (UK)  
F. COSMAN (US)  
L. DE MARINIS (I)  
L. DEGLI ESPOSTI (I)  
D. DEMPSTER (US)  
M. DOGA (I)  
R. EASTELL (UK)  
P. EBELING (AUS)  
H. FALHAMMAR (S)  
A. FATHI KAZEROONI (USA)  
S. FERRARI (CH)  
M. FLESERIU (US)  
A.M. FORMENTI (I)  
S. FRARA (I)  
E. GHIGO (I)  
S. GIANNINI (I)  
A. GIUSTINA (I)  
C. GLUER (D)  
S. GONNELLI (I)  
M. HEWISON (UK)  
G. IOLASCON (I)  
B. LANGDHAL (DK)  
A. LINGLART (F)  
P. MAKRAS (GR)  
C. MARCOCCI (I)  
L. McCABE (US)  
S. MINISOLA (I)  
N. NAPOLI (I)  
R. NUTI (I)  
A. ODONE (I)  
R. PACIFICI (US)  
S. PAPAPOULOS (NL)  
R.J. PIGNOLO (US)  
M. RAUNER (D)  
I.R. REID (NZ)  
L. REJNMARK (DK)  
R. RIZZOLI (CH)  
C. ROSEN (US)  
K. SAAG (US)  
A. SCILLITANI (I)  
D. SHOBACK (US)  
H. SIGGELKOW (D)  
F.M. ULIVIERI (I)  
A.J. VAN DER LELIJ (NL)  
G. WEBER (I)



# GENERAL INFORMATION

## Italian CME ACCREDITATION AND LANGUAGE

The 9<sup>th</sup> eSEM LEE programme has received nr. **15 CME credits (ID CME: 5468 - 311092)**  
Scientific Coordinator: Prof. Pietro Mortini - Direttore U.O. di Neurochirurgia - IRCCS Ospedale San Raffaele - Milano)  
for physiotherapists, nurses, biologists, dieticians and physicians: Endocrinology, Metabolic Diseases and Diabetology, Geriatrics, Emergency Medicine, Physical Medicine and Rehabilitation, Internal Medicine, Sport Medicine, Oncology, General Medical Practice, Nephrology, Rheumatology, Gynaecology and Obstetrics, Neurosurgery, Orthopaedics and Traumatology, Clinical Biochemistry, Nuclear Medicine, Clinical Pathology, Epidemiology, Pediatrics, General Surgery, Palliative Care, Pharmacology and Toxicology, Legal Medicine, Ophthalmology, Dietetics and Urology.  
The official language is English. Translation will be not provided

## EDUCATIONAL TARGET

Application of Evidence-Based-Practice (EBM-EBN-EBP)  
principles and procedures in daily practice

## LOCAL ORGANIZING COMMITTEE

L. Castellino (I), M. Doga (I), A.M. Formenti (I), S. Frara (I),  
P. Loli (I), P. Mortini (I), F.M. Ulivieri (I)

## ORGANIZING SECRETARIAT and PROVIDER (ID 5468)

**A.I.C. Asti Incentives & Congressi**

Ph. +39 050 598808 - Fax +39 050 0987825  
skeletal2021@aicgroup.it - www.aicgroup.it

## REGISTRATION

Online registrations are open. Please visit [www.gioseg.org](http://www.gioseg.org) to register

Delegate registration fee € 150,00 + 22% taxes

(fee includes: participation to live event, Ecm/Eaccme certificate, possibility to download all educational material registered during the meeting)



# AKNOWLEDGMENTS

With the unrestricted support of



**ABIOGEN**  
PHARMA



